

1652
1



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Mukerji, et al.

Group Art Unit: 1652

Serial No.: 09/624,670

Certificate of Mailing under 37 CFR §1.8(a):

Filed: July 24, 2000

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as First Class Mail addressed to as follows:

For: ELONGASE GENES AND USES THEREOF

Attorney Docket No.: 6407.US.P2

Assistant Commissioner for Patents
Washington, D.C. 20231

Examiner: Tung, P.

Date of Deposit: 12/2

Kimberly A. Iorio
Kimberly A. Iorio

RECEIVED
JAN 18 2002
TECH CENTER 1600 2930

TRANSMITTAL LETTER

Assistant Commissioner for Patents
Washington, DC 20231

Dear Sir:

Enclosed herewith for the patent application identified above entitled ELONGASE GENES AND USES THEREOF are the following:

1. Preliminary Amendment (32 Pages)
2. Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (1 Page)
3. Paper Copy of Sequence Listing (46 Pages)
4. Computer Readable Form Copy (1 Diskette)
5. Response to Notice to Comply and Statement to Support Filings and Submissions (1 Page)
6. Request for Extension of Time, in duplicate (1 Page)
7. Return Receipt Postcard

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR § 1.16, as well as any patent application processing fees under 37 CFR

\$ 1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025. A duplicate copy of this sheet is enclosed.



23492

ABBOTT LABORATORIES

Telephone: (847) 938-7576

Facsimile: (847) 938-2623

Respectfully submitted,
Mukerji, et al.

Cheryl L. Becker

Cheryl L. Becker


Registration No. 35,441

Attorney for Applicants

Application No.: 09/625,790

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

RECEIVED

JAN 1 8 2002

TECH CENTER 1600 2900

152
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Mukerji, *et al.*

Group Art Unit: 1652

Serial No.: 09/624,670

Certificate of Mailing under 37 CFR §1.8(a):

Filed: July 24, 2000

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as First Class Mail addressed to as follows:


For: ELONGASE GENES AND USES THEREOF

Attorney Docket No.: 6407.US.P2

Examiner: Tung, P.

Assistant Commissioner for Patents
Washington, D.C. 20231

Date of Deposit: 12-66



Kimberly A. Iorio



RECEIVED
JAN 17 2002
TECH CENTER 1600-2900

TRANSMITTAL LETTER

Assistant Commissioner for Patents
Official Draftsperson
Drawing Review Branch
Washington D.C. 20231

Dear Sir:

Enclosed herewith for the patent application identified above entitled ELONGASE GENES AND USES THEREOF are the following:

1. Submission of Formal Drawings;
2. Formal Drawings, 82 Sheets (FIG. 1 – FIG. 63B); and
3. Return Receipt Postcard.


The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 C.F.R. §1.16, as well as any patent application processing fees under 37 C.F.R. §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025. A duplicate copy of this sheet is enclosed.



23492

ABBOTT LABORATORIES
Telephone: (847) 938-7576
Facsimile: (847) 938-2623

Respectfully submitted,
Mukerji, *et al.*



Cheryl L. Becker
Registration No. 35.441
Attorney for Applicants

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Mukerji, *et al.*


Serial No.: 09/624,670

Filed: July 24, 2000

For: ELONGASE GENES AND USES
THEREOF

Attorney Docket No.: 6407.US.P2

Examiner: Tung, P.



Group Art Unit: 1652

**Certificate of Mailing under 37 CFR
§1.8(a):**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as First Class Mail addressed to as follows:

Assistant Commissioner for Patents
Washington, D.C. 20231

Date of Deposit: 1-20-02

Kimberly A. Iorio

TECH CENTER 600 60

RECEIVED

SUBMISSION OF FORMAL DRAWINGS

Assistant Commissioner for Patents
Official Draftsperson
Drawing Review Branch
Washington D.C. 20231

Dear Sir:

Transmitted herewith are 82 sheets (FIG. 1 – FIG. 63B) of corrected formal drawings. Please replace the originally filed informal drawings with the formal drawings submitted herewith. If any problems exist with the enclosed Formal Drawings, the undersigned would appreciate a telephone call from the Draftsman as soon as possible.



23492

ABBOTT LABORATORIES
Telephone: (847) 938-7576
Facsimile: (847) 938-2623

Respectfully submitted,
Mukerji, *et al.*

Cheryl L. Becker
Registration No. 35,441
Attorney for Applicants